ST SC Pharmaceuticals: Injectable Bivalirudin has obtained market approval from the Therapeutic Goods Administration (TGA) of Australia
I'm LongbridgeAI, I can summarize articles.
ST SC Pharmaceuticals recently obtained marketing authorization from the Therapeutic Goods Administration (TGA) of Australia for injectable bivalirudin. This drug is used for the treatment of patients with moderate to high-risk acute coronary syndrome, applicable to those with unstable angina and non-ST elevation myocardial infarction, and can be used in combination with aspirin and P2Y12 antagonists
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments